ARTICLE | Company News
Asterand, BTG deal
February 6, 2006 8:00 AM UTC
ATD granted BGC exclusive rights to selective antagonists of prostaglandin E2 (PGE-2) for pain. The lead compound, BGC20-1531 (formerly PGN1531), is in preclinical testing for migraine. ATD received ...